994 F.3d 484
5th Cir.2021Background
- Under the Hatch–Waxman Act, the first generic filer can gain 180 days of market exclusivity; a brand suit within 45 days triggers a 30‑month FDA stay that delays generic approval.
- Endo marketed Opana ER (extended‑release oxymorphone); Impax filed the first generic ANDA in 2007; Endo sued for patent infringement in 2008, triggering the stay.
- In June 2010, shortly after FDA tentative approval of Impax’s ANDA, Endo and Impax settled: Impax agreed to delay launch until Jan 1, 2013; Endo agreed not to market an authorized generic during Impax’s 180‑day exclusivity and paid credits and up‑front/contingent payments (ultimately >$100 million), plus a $10M immediate payment tied to a collaboration.
- Endo executed a product hop (reformulated Opana ER), shrinking the original‑formulation market; it later paid Impax about $102M in credits; Endo obtained further patents and injunctions against other generics and eventually withdrew the reformulation after FDA safety concerns.
- The FTC challenged the settlement as an unlawful reverse payment (antitrust). An ALJ found the agreement restricted competition but lawful on balance; the full Commission reversed, found no procompetitive justification and viable less‑restrictive alternatives, and issued a cease‑and‑desist order against Impax.
- The Fifth Circuit reviewed legal errors and substantial‑evidence support for the FTC’s findings and denied Impax’s petition for review.
Issues
| Issue | Plaintiff's Argument (FTC) | Defendant's Argument (Impax) | Held |
|---|---|---|---|
| Whether the settlement had anticompetitive effects (i.e., was a reverse payment that foreclosed competition) | Large, unjustified payments and Endo’s concessions bought exclusion and replaced possible competition with certainty of none | Payment reflected legitimate settlement value (litigation avoidance, services); not evidence of anticompetitive effect | Held for FTC: large, unjustified payments plus context (FDA approval, product‑hop plans) supported inference of anticompetitive effect under Actavis |
| Whether the Commission had to assess patent strength / litigate patent validity to show anticompetitive effect | Not required; a large unexplained reverse payment is a workable surrogate for patent weakness and anticompetitive risk | Argues Actavis requires court to weigh patent strength (likelihood brand would have won) before inferring anticompetitive effect | Held for FTC: Actavis rejects requirement to litigate patent validity; payment size can substitute for patent‑strength inquiry |
| Whether the settlement produced cognizable procompetitive benefits tied to the challenged restraint | Any procompetitive benefits were not tied to the reverse payment itself; claimed benefits (earlier entry, licenses) did not justify the large payment | Settlement advanced procompetitive benefits (earlier entry than patent expiry, licenses, collaboration) that outweighed harms | Held for FTC: Commission found no nexus between reverse payment and procompetitive benefits (and alternatively treated benefits as achievable without payment) |
| Whether less‑restrictive alternatives (e.g., no‑payment settlement with earlier entry) were feasible | A no‑payment settlement with equal or earlier entry was practicable (industry practice, economic analysis, witness credibility issues) | Impax contends a no‑payment, earlier‑entry deal was infeasible and the Commission shifted burden | Held for FTC: substantial evidence (industry data, credibility findings, economic logic) supported existence of less‑restrictive alternatives; settlement was unreasonable |
Key Cases Cited
- 570 U.S. 136 (Sup. Ct. 2013) (holding reverse‑payment patent settlements are evaluated under the rule of reason; large unexplained payments suggest anticompetitive effect)
- 138 S. Ct. 2274 (Sup. Ct. 2018) (articulating burden‑shifting framework for rule‑of‑reason analysis)
- 476 U.S. 447 (Sup. Ct. 1986) (deference to FTC’s informed judgment and substantial‑evidence standard for agency factfinding)
- 842 F.3d 34 (1st Cir. 2016) (explaining reverse payments can prolong a bottleneck and delay subsequent generic competition)
- 300 F.3d 620 (5th Cir. 2002) (describing balancing step in rule‑of‑reason analysis)
- 868 F.3d 132 (3d Cir. 2017) (finding large payments in settlement supported inference of anticompetitive effect)